http://orcid.org/0000-0001-7898-7720
References
- Vichinsky E. Complexity of α thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. Ann N Y Acad Sci. 2010;1202(1):180–187.
- Surapolchai P, Chuansumrit A, Sirachainan N, et al. A molecular study on the role of α-hemoglobin-stabilizing protein in hemoglobin H disease . Ann Hematol. 2017;96(6):1005–1014.
- Ebrahimkhani S, Azarkeivan A, Bayat N, et al. Genotype-phenotype correlation in Iranian patients with Hb H disease. Hemoglobin. 2011;35(1):40–46.
- Tsamesidis I, Fozza C, Vagdatli E, et al. Total antioxidant capacity in Mediterranean β-thalassemic patients. Adv Clin Exp Med. 2017;26(5):789–793.
- Rujito L, Mulatsih S, Sofro AS. Status of superoxide dismutase in transfusion dependent thalassaemia. North Am J Med Sci. 2015;7(5):194–198.
- Rasool M, Malik A, Jabbar U, et al. Effect of iron overload on renal functions and oxidative stress in β thalassemia patients. Saudi Med J. 2016;37(11):1239–1242.
- Chui DHK. α-Thalassemia: Hb H disease and Hb Bart’s hydrops fetalis. Ann NY Acad Sci. 2005;1054(1):25–32.
- Fucharoen S, Viprakasit V. Hb H disease: clinical course and disease modifiers. Hematology Am Soc Hematol Educ Program. 2009;2009(1):26–34.
- Ünal Ş, Gümrük F. The hematological and molecular spectrum of α-thalassemias in Turkey: the Hacettepe experience . Turk J Haematol. 2015;32(2):136–143.
- Taher A, Vichinsky E, Musallam K, et al. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). In: Weatherall D, Editor. Thalassaemia International Federation (c) 2013. Nicosia (Cyprus): Thalassaemia International Federation, 2013.
- Yang G, Liu R, Peng P, et al. How early can myocardial iron overload occur in β thalassemia major? Plos One. 2014;9(1):e85379
- Karimi M, Amirmoezi F, Haghpanah S, et al. Correlation of serum ferritin levels with hepatic MRI T2 and liver iron concentration in nontransfusion β-thalassemia intermediate patients: a contemporary issue. Pediatr Hematol Oncol. 2017;34(5):292–297.
- Zhao N, Zhang A, Enns CA. Iron regulation by hepcidin. J Clin Invest. 2013;123(6):2337–2343.
- Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–684.
- Afanas’Ev IB. Interplay between superoxide and nitric oxide in thalassemia and Fanconi’s anemia. Hemoglobin. 2006;30(1):113–118.
- Chiou S, Tsao C, Tsai S, et al. Metabolic pathways related to oxidative stress in patients with Hemoglobin H disease and iron overload. J Clin Lab Anal. 2014;28(4):261–268.
- Elalfy MS, Adly AA, Attia AA, et al. Effect of antioxidant therapy on hepatic fibrosis and liver iron concentrations in β-thalassemia major patients. Hemoglobin 2013;37(3):257–276.
- Adhiyanto C, Hattori Y, Yamashiro Y, et al. Oxidation status of β-thalassemia minor and Hb H disease, and its association with glycerol lysis time (GLT50). Hemoglobin 2014;38(3):169–172.
- Elsayh KI, Zahran AM, El-Abaseri TB, et al. Hypoxia biomarkers, oxidative stress, and circulating microparticles in pediatric patients with thalassemia in Upper Egypt. Clin Appl Thromb Hemost. 2014;20(5):536–545.